Research
Micronutrients & recovery
Engineered E. coli Nissle strains (SYNB1618 and SYNB1934) expressing phenylalanine-degrading enzymes successfully reduce fasting plasma phenylalanine levels in patients with Phenylketonuria (PKU) in Phase 1/2a and Phase 2 trials.
For PKU patients, engineered bacteria are showing promise in clinical trials to lower blood phenylalanine levels. This could eventually offer more dietary flexibility, but these treatments are not yet widely available.
GoodSupportsHIGH confidence
This strain was further engineered (SYNB1934) to generate higher bacterial PAL activity... both strains demonstrated clinically meaningful reductions in fasting plasma Phe (www.synlogictx.com).
Why this rating
Positive results in Phase 1/2a and Phase 2 trials; pivotal Phase 3 planned.
Source
Engineering bacteria to modulate host metabolism
Dragos Ciocan et al. · Acta Physiologica · 2023
narrative_reviewCited 16×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →